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Abstract : Objective: Porphyria Cutanea Tarda results from decrease hepatic uroporphyrinogen decarboxylase activity. There are two 
principal types: sporadic or acquired and familial or hereditary Porphyria Cutanea Tarda. Hereditary Porphyria Cutanea Tarda is 
observed in 25-30% of the patients in whom one allele of the uroporphyrinogen decarboxylase gene reduces the enzyme activity by 
approximately 50% in all tissues. There are experimental evidences that suggest a possible relationship between CYP1A1, CYP1A2 and 
Porphyria Cutanea Tarda symptomatology development but the results described in different populations are very conflictive.The aim of 
this work is provide additional evidences about the participation of the CYP system on the manifestation of this disease. 
Subjets/Methods: We analyse the polymorphisms already described in these CYPs isoforms in 112 Porphyria Cutanea Tarda Argentinian 
patients and 89 controls. Of these 64 were used for haplotype analysis. The polymorphisms were detected by RFLP-PCR or sequencing.    
Results: For CYP1A2*1F polymorphism C allele (wt) was exceptionally the less frequent while the polymorphic A allele, with an increased 
transcriptional activity, resulted to be the risk allele.  
For CYP1A1 m4 polymorphism, for which are not previous reports about this effect, our results indicated that the A variant would be a 
risk factor to develop the disease.  
For m2 polymorphism we obtained contradictory results depending on the groups compared.   
The risk haplotype calculated with the snpSTATs was m4-m2-m1-1A2: C-G-C-C.   
Conclusions: These results indicated that, among other factors, these polymorphisms would be related with Porphyria Cutanea Tarda 




   The porphyrias are a group of metabolic diseases which 
results from the partially deficiency of one of the enzymes of 
the heme biosynthetic pathway (Fig. 1). 
 
 
Figure 1. Pathway of heme biosynthesis. Heme biosynthesis  
 
begins in the mitochondria from glycine and succinyl-CoA, 
continues in the cytosol, and ultimately is completed within 
the mitochondria. PBG: porphobilinogen, ALA: ä-
aminolevulinic acid. URL: https://www.google.com.ar/heme 
biosynthesis. 
 
  Porphyria Cutanea Tarda (PCT; OMIM 176100), the most 
common type of porphyria, is due to a decreased activity of 
uroporphyrinogen decarboxylase (UROD; E.C.4.1.1.37). This 
cytosolic enzyme catalyzes the fifth step in the heme 
biosynthetic pathway (Fig. 1), the sequential decarboxylation 
of the four acetate side chains of uroporphyrinogen to form 
coproporphyrinogen [1,2]. PCT usually develops in 
adulthood and is characterized by hepatic accumulation of 
uroporphyrinogen and other highly carboxylated 
porphyrinogens that circulate in plasma and are excreted in 
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urine as porphyrins [2,3]. The overproduction of porphyrins 
is the reason for the major clinical manifestations of the 
disease, cutaneous photosensitivity with blistering on areas 
exposed to sun, skin fragility, hyperpigmentation and 
hypertrichosis [2]. Three clinically similar forms of PCT can 
be distinguished: A-PCT (acquired PCT), H-PCT (hereditary 
PCT) and type III PCT [2,4,5]. H-PCT is an autosomal 
dominant disorder with low penetrance in which the UROD 
activity is reduced to about 50% in all tissues due to 
mutations in heterozygosis in the UROD gene. H-PCT 
represents about 25-30% of PCT patients. Most PCT patients 
are A-PCT, without mutations in the UROD gene and the 
deficiency in enzymatic activity is restricted to the liver 
[2,4,5]. Type III PCT is a rare form similar to A-PCT but, 
while the A-PCT does not show a familial pattern, type III 
PCT is associated with a familial history for the disease [5]. 
The clinical manifestation of PCT is frequently associated 
with exposure to precipitating factors including iron 
overload, alcohol abuse, use of estrogens, hepatitis C virus 
infection and other hepatothropic virus, nitrosamines from 
tobacco smoke, etc. [2,3,68]. Hereditary hemochromatosis 
associated with the HFE gene is the most common genetic 
cause of iron overload and inheritance of HFE mutations is 
prevalent in PCT patients in some countries [7]. Otherwise, 
mutations in HFE gene do not play a relevant role in the 
triggering of PCT in Argentina [9]. 
 
  The clinical expression of the disease is a consequence of a 
marked deficiency in the UROD activity in the liver caused 
by a competitive inhibitor (uroporphomethene) generated in 
an iron-dependent oxidation of uroporhyrinogen [10].  
 
   There are experimental evidences that suggest a possible 
relationship between CYP1A1, CYP1A2 and PCT 
symptomatology development. In a murine model it was 
demonstrated that the porphyrinogenic agent 
hexaclorobencene (HCB) induced hepatic accumulation of 
URO, due to the formation of metabolites, products of the 
biotransformation of HCB by those isoforms, inhibiting the 
hepatic URO-D [11]. Moreover employing murine models of 
PCT it was observed that UROD activity was inhibited by a 
product of the oxidation of Urogen (uroporphometene) by the 
CYP1A2 [10].  
 
   So, considering that some of the drugs not recommended 
for use in porphyric patients are metabolized by these CYPs, 
the presence of polymorphisms in these molecules would 
influence the Porphyria triggering. 
 
   CYP1A1 is involved in the metabolization of estrogens and 
carcinogens to their inactive derivatives but occasionally 
converts the chemicals to more potent carcinogens. SNPs are 
reported in CYP1A1 and has been described that the 
frequencies are highly variable between ethnicities and 
populations. The CYP1A1*2A, rs4646903 (m1 
polymorphism) is a T to C transition at 6235 position located 
in the 3 non-coding region creating a MspI restriction site. 
The CYP1A1*2C, rs1048943, (m2 polymorphism) is an A to 
G transition giving rise to a HincII restriction site at position 
4889 in exon 7 changing the isoleucine to valine at codon 462 
in heme binding region. The m3 polymorphism is a T to C 
transition at position 5639 which creates a MspI restriction 
site in 3' non-coding region only found in African American 
population. The CYP1A1*4, rs.1799814 (m4 polymorphism) 
which have not been extensively studied, is a C to A 
transversion at position 4887 leading the threonine to 
asparagine substitution at codon 461 which leads to the loss 
of a BsaI restriction site [12,13]. 
 
  The CYP1A2 gene cluster has been mapped on 
chromosome 15q24.1, with close link between CYP1A1 and 
CYP1A2 sharing a common 5-flanking region. CYP1A2 is 
located approximately 25 kb away from CYP1A1 on 
chromosome 15. Human CYP1A2 is one of the main CYPs 
in human liver and metabolizes a number of several clinical 
drugs (clozapine, tacrine, tizanidine, and theophylline; some 
procarcinogens (benzo[á]pyrene and aromatic amines) and 
several important endogenous compounds (steroids). 
CYP1A2 is subject to reversible and/or irreversible inhibition 
by a number of drugs, natural substances and other 
compounds. A large interindividual variability in the 
expression and activity of CYP1A2 has been observed, which 
is largely caused by genetic, epigenetic and environmental 
factors.  
 
  To date, more than 15 variant alleles and series of 
subvariants of the CYP1A2 gene have been identified and 
some of them have been associated with altered drug 
clearance and disease susceptibility. One of the most studied 
is the promoter variant C/A in the intron region at nucleotide 
-163 bp. Although C allele is consider the wt, A allele is the 
most frequent in the population and increases the amount of 
the enzyme and so its catalytic capacity, C give rise to a 
restriction site for ApaI.  
 
   Epidemiological studies have shown inconsistent results 
about CYP1A1 and CYP1A2 polymorphisms and porphyria 
development among various populations ([14], [15], [16], 
[17]) so we decided to investigate the presence or not of these 
polymorphisms in our population and if they are related to 
PCT development. 
 
II. MATERIALS/SUBJETS and METHODS 
 
1.  Subjects 
 
    A total of 112 samples: 36 H-PCT, 76 A-PCT and 89 
controls, carefully selectionated for not being consumers of 
porphyrinogenic drugs through an oral questionare were 
included in the study. We calculated genotype and allele 
frequencies; risk genotype and allele were estimated with the 
vccSTATs. Of these 112 samples, 64: 24 controls, 23 F-PCT, 
17 A-PCT were used to estimate the risk haplotype with 
snpSTATs. 
 
  Mean age at PCT diagnosis was 47,5 years (2377 years) 
and the average age of appearance of the first manifestations 
was 42 years (range from 27 to 61 years). 
 
2.   Methods 
 
   Biochemical studies included plasma porphyrins index 
(PPI) and total urinary porphyrins (UTP) with its 
corresponding chromatography in thin layer showing a 
preponderance of highly carboxylated porphyrins [18].  
 
    UROD activity was about 50% diminished in cases of H-
PCT which were also genetically diagnosted [19].   
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    Genomic DNA was extracted from EDTA whole blood 
samples using Illustra blood genomic Prep Mini spin Kit 
(Bioneer). Target DNA was amplified with the corresponding 
pair of primers (Sigma-Aldrich) depending on the fragment 
to be amplified in each CYP (Table1) and then treated with 
the corresponding restriction enzymes: ApaI, BsaI and HincII 
(New England Biolabs) and also by sequencing (Macrogen) 




Table 1. PCR primers for the study of polymorphisms of 
CYPs1A1 (m2-m4) and CYP1A2. 
 
3. Statistical Analysis  
 
   The genotype and allele frequencies were estimated for 
each group and polymorphism. The statistic was done with 
snpSTATS.   
 
   With vccSTATs we contrasted each PCT group with 
controls (in a contingence table 2x2) to estimate risk 
genotype or allele with the parameters: odds ratio (OD), p 
Fisher<0.05 and 95 % confidential interval (CI).  
 
    The mutant genotype or allele was contrasted with the wt 
to estimate the risk allele and genotype. 
 
    The risk haplotype was calculated using the snpSTATS 
program contrasting each group of PCT with controls 
supposing that our population meet the Hardy-Weinberg law.  
 
4. Databases 
     
    The Human Database https://www.ncbi.nlm.nih.gov/ was 
used for information about reported polymorphisms in these 
genes. 
 
5.  Ethical approval and consent to participate 
 
    Informed consent was obtained from all patients following 
the standards of UNESCO Declarations-DD.HH. Genome 
and Genetic Data (www.unesco.org/shs/ethics), Declaration 
of Helsinki was followed and the study was approved by the 
Institutional Research Ethics Committee of the Research 
Center on Porphyrins and Porphyrias (CIPYP) - National 
Scientific and Technical Research Council (CONICET), 




   The following Figures show the allele and genotype 
frequencies calculated for the different polymorphisms in 
subgroups stratified by familial, acquired and total PCT 
patients and controls. 
In all cases the genotype or allele more frequent is 
put first except for CYP1A2*1F. 
 
Polymorphism CYP1A2*1F (-163 C/A):  
Figures 2 and 3 show the genotype and allele frequencies for 








Figure 3. Allele frequencies for CYP1A2*1F (C/A) 
 
Applying vccSTATs program significant results are present 




Table 2. Statistic with genotype frequencies 
 
CYP1A1: 
Polymorphism CYP 1A1*4 (m4):                                                         
 
Figures 4 and 5 show the genotype and allele frequencies for 
this polymorphism respectively. 
CYP1A1 
 
m2m4 F: 5 GAACTGCCACTTCAGCTGTCT 3 
m2m4 R: 5 GAAAGACCTCCCAGCGGTCA  3 
CYP1A2       
 
1A2 F: 5 GGAAGGTATCAGCAGAAAGCC 3 
1A2 R: 5 GGCTCATCCTTGACAGTGCC    3  
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Figure 5. Allele frequencies of m4 polymorphism (C/A) 
 
 Applying vccSTATs program significant results are present 




Table 3. Statistic with genotype and allele frequencies. 
 
Polymorphism CYP 1A1*2C (m2): 
Figures 6 and 7 show the genotype and allele frequencies for 
the polymorphism respectively. 
 
 




Figure 7. Allele frequencies of m2 polymorphism (A/G) 
 
Applying vccSTATs program significant results are present 
in Table 4. 
 
A-PCT vs Controls A/G vs A/A 
H-PCT vs A-PCT A/G vs 
A/A 
OR=0.45               0.24<CI<0.84 
OR=2.36                 
1.02<IC<5.47 
pf= 0.0090 pf=0.036 
Protection genotype Risk genotype 
 




   The haplotype estimated with the snpSTATs was C-G-C-C, 
only significative for H-PCT vs controls.  
In the Table 5 are shown comparatively the results presented 
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CYP1A2                                 FGGF                         AF
study group subtype of PCT n %C/C % C/A % A/A %C %A
Argentina I & II 115 7 40 53 27 73
I 77 9.0% 35 56 27 73
II 38 3 50 47 28 72
Controls 83 17 37 46 36 64
USA I & II 66 5.8 39.1 55.1 25 75
I 50 4 36 60 22 78
II 16 13 56 31 41 59
Controls 72 12.5 51.4 36.1 38 62
Denmark I & II 53 5.7 22.6 71.7 17 83
I 40 2.5 27.5 70 16 84
II 13 15.4 7.7 76.5 19 81
Controls 60 10 43.3 46.7 32 68
France I & II 49 6.1 53.1 38.8 33 67
I 45 ND ND ND ND ND
II 4 ND ND ND ND ND
Controls 48 12.5 47.9 39.6 37 64
Spain I & II 102 2.9 49 48 28 73
I 80 2.5 52.5 45 29 71
II 22 4.5 36.5 59.1 23 77
Controls 150 12 48 40 36 64
CYP1A1 m4                                FGGF                                                                        AF
study group  PCT subtype n % C/C % C/A %A/A %C %A
Argentina I & II 111 67 29 4 81 19
I 73 70 30 0 85 15
II 38 60 26 14 74 26
Controls 90 59 39 2 78 22
USA I & II 71 97.2 2.8 0 98.6 1.4
I 53 96 4 0 98 2
II 16 100 0 0 100 0
Controls 70 91.4 8.6 0 95.7 4.3
Germany I & II 46 82.6 17.4 0 85.3 14.7
I 29 89.7 10.3 0 94.8 5.2
II 17 70.6 29.4 0 85.3 14.7
Controls 101 92.6 7,4 0 100 0
CYP1A1 m2                                                  GFGF                                                                        AF
study group PCT subtype n % A/A % A/G %G/G %A %G
Argentina I & II 110 61 38 1 80 20
I 78 67 32 1 83 17
II 32 47 53 0 73 27
Controls 93 48 52 0 74 26
USA I & II 72 90 9 1 94 6
I ND 90 10 ND 95 5
II ND 100 ND ND 100 ND
Controls ND 85 11 4 90 10  
 
 
Table 5. Genotype and allele frequencies published by 
Wickliffe et al 2011, Gardlo 2003 et al. and our study. 
   
IV. DISCUSSION   
 
   Previous reports have indicated that CYP1A21*F promotor 
variant A in intron 1 at nucleotide position -163 bp, increases 
the amount of the enzyme by augmenting its transcriptional 
activity and stability of the transcript [16]. Our results give us 
the same tendency and this will be related with the increase 
of the susceptibility to develop PCT. It is a rare case in which 
the polymorphic A allele is the more frequent in the studied 
population and others. 
  
   For CYP1A1, there is not previous report of the effect of 
m4 polymorphism and the susceptibility to develop this 
disease. The predict snp give rise that the aminoacid change 
will have not effect in the development of any pathology and 
the effect of nucleotide change could not be analyzed. Our 
studies showed that C allele (wt) is the more frequent and A 
allele was a risk factor to develop the PCT.  
 
   In the case of m2 polymorphism the A allele is the wt and 
is the more frequent. Previous reports have shown that the G 
variable (mutated) produces an aminoacid change increasing 
the CYP activity [13,20], ROS species and the susceptibility 
to develop cancer [12,13]. The same was demonstrated in our 
work for the PCT when we contrasted the H-PCT vs A-PCT 
groups for the genotype A/G vs A/A. In this case the increase 
of ROS would lead to the oxidation of uroporphyrinogen to 
uroporphomethene (competitive inhibitor) or to uroporphyrin 
(not metabolizable), being both risk factors to develop the 
Porphyria. Another alternative would be the direct oxidation 
of the cysteine, histidine and lysine in the active site of the 
enzyme. Instead, for A-PCT vs control group for the same 
genotypes previously contrasted, an unexpected result was 
obtained in which G allele could be a protection factor. We 
propose here that the xenobiotic itself would direct inhibit the 
enzyme.           
 
   For m1 polymorphism CYP1A1 (rs.4646903) in the 3 
region the T6235C change increase the catalytic activity in 
China population [21]. In our case we have not significative 
differences in the contrasted groups for all genotypes and 
alleles but we need to increase the number of patients for a 
more secure statistic.     
 
   Other polymorphism of the CYP1A1 described in the 
literature is the m3: T5639C (intrón 7) only present in the 
African population. 
 
   For haplotype analysis with the snpSTATs contrasting each 
group of PCT vs Controls, only significative difference was 
found for H-PCT in which the risk haplotype was for m4-m2-
m1-1A2: C-G-C-C.  
 
   All the differences found with other populations (Table 5) 
might be due to ethnicities differences among the various 
underling susceptibility factors to develop the PCT.   
 
   This is the first study of these polymorphisms in our 
population. We think that our results are relevant to Human 
health contributing in the future to prevent the development 
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LIST OF ABBREVIATIONS 
 
ALA                  ä -aminolevulinic acid 
A-PCT               Acquired PCT 
AhR              Aryl hydrocarbon receptor 
Bp     Base pair 
CI              Confidential interval 
DNA              Desoxirribonucleic acid 
H-PCT              Hereditary PCT 
HCB              Hexaclorobencene 
HFE              Hemochromatosis 
H-PCT              Hereditary PCT 
OD              Odds ratio 
PBG  Porphobilinogen 
PCR  Polymerase chain reaction 
PCT  Porphyria Cutanea Tarda 
PPI                Plasma Porphyrins Index 
RFLP-PCR        Restriction Fragment Length Polymorphism 
ROS             Reactive Oxygen Species 
SNP             Single nucleotide polymorphism 
A-PCT               Sporadic PCT 
URO-D              Uroporphyrinogen decarboxylase 
UTP             Urinary Total Porphyrins 
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